Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT2306 versus Cosentyx in moderate to severe plaque psoriasis
2022-001770-59Phase 3Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing BAT2306 with Cosentyx (2 arms). Primary endpoint: Percent change from baseline in PASI score at Week 8. Started Jul 2022; status: completed.
02
Drugs
BAT2306secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-001770-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001770-59.